EDP Biotech goes to Path C that also opens-up some new opportunities

Tom Ballard, Chief Alliance Officer, PYA has recently had a chat with our own Eric Mayer, CEO of EDP Biotech. They talked about start-ups and how EDP Biotech is moving forward. Here is a little bit of that article. Head over to Teknovations.biz for the full story. We had the chance to talk a bit about our new product, ColoPlex and our plans for future growth.

One of the pieces of advice that start-up entrepreneurs receive is to have one or more back-up plans in their back pocket in case their first path forward does not produce the results they wanted.

That’s certainly the case with EDP Biotech Corporation, according to Eric Mayer, the Knoxville-based company’s Chief Executive Officer (CEO), echoing the philosophy of company Founder and serial entrepreneur Tom Boyd who says: “keep trying new things until you find what works.”

With March being National Colorectal Cancer Awareness Month, we wanted to get an update on the progress the start-up is making in developing products, initially for colorectal cancer detection, to identify and purify proteins present in the early stages of biological changes in an individual.

“We’ve made a pretty big pivot,” Mayer told us in our recent conversation. “We’re building a new product and going after a faster path to market in a slightly different (part of the colon cancer screening) market segment, using state-of-the-art data science to solve a complex biologic problem.” EDP’s goal remains detection of early-stage cancers and precancerous polyps, but doing so in a more cost-effective manner for healthcare systems.